NO20032986D0 - Metoder og blandinger for påvisning av forbindelser som modulerer inflammatoriske responser - Google Patents
Metoder og blandinger for påvisning av forbindelser som modulerer inflammatoriske responserInfo
- Publication number
- NO20032986D0 NO20032986D0 NO20032986A NO20032986A NO20032986D0 NO 20032986 D0 NO20032986 D0 NO 20032986D0 NO 20032986 A NO20032986 A NO 20032986A NO 20032986 A NO20032986 A NO 20032986A NO 20032986 D0 NO20032986 D0 NO 20032986D0
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- compounds
- detection
- methods
- inflammatory responses
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25930600P | 2000-12-29 | 2000-12-29 | |
PCT/US2001/050818 WO2002066978A2 (en) | 2000-12-29 | 2001-12-21 | Detection of compounds that modulate inflammatory responses |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20032986D0 true NO20032986D0 (no) | 2003-06-27 |
NO20032986L NO20032986L (no) | 2003-08-13 |
Family
ID=22984398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20032986A NO20032986L (no) | 2000-12-29 | 2003-06-27 | Metoder og blandinger for påvisning av forbindelser som modulerer inflammatoriske responser |
Country Status (11)
Country | Link |
---|---|
US (1) | US7273712B2 (no) |
EP (1) | EP1368648A2 (no) |
JP (1) | JP2005501222A (no) |
BR (1) | BR0116606A (no) |
CA (1) | CA2433348A1 (no) |
HU (1) | HUP0600450A2 (no) |
IL (1) | IL156651A0 (no) |
IS (1) | IS6861A (no) |
NO (1) | NO20032986L (no) |
PL (1) | PL366250A1 (no) |
WO (1) | WO2002066978A2 (no) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL155174A0 (en) * | 2000-10-02 | 2003-10-31 | Reddy Us Therapeutics Inc | Methods and compositions for the treatment of inflammatory diseases |
BR0116606A (pt) * | 2000-12-29 | 2006-05-09 | Reddy Us Therapeutics Inc | métodos e composições para detecção de compostos que modulam as respostas inflamatórias |
EP1575513A4 (en) * | 2002-08-16 | 2007-04-04 | Wyeth Corp | COMPOSITIONS AND METHODS FOR TREATING RAGE-ASSOCIATED DISEASES |
WO2005040163A1 (en) * | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
US20060078562A1 (en) * | 2004-08-03 | 2006-04-13 | Mjalli Adnan M | RAGE fusion proteins and methods of use |
WO2006017647A1 (en) * | 2004-08-03 | 2006-02-16 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
US20060084184A1 (en) * | 2004-10-19 | 2006-04-20 | Renovar Incorporated | Reagents for urine-based immunological assays |
CN101331384B (zh) * | 2005-12-23 | 2011-11-09 | G科德系统有限公司 | 定位图形 |
ES2421595T3 (es) | 2006-01-10 | 2013-09-04 | Colgate Palmolive Co | Métodos para modular receptores de superficie celular para prevenir o reducir la inflamación |
BRPI0707640A2 (pt) * | 2006-02-09 | 2011-05-10 | Transtech Pharma Inc | proteÍnas de fusço do rage e mÉtodos de uso |
EA017291B1 (ru) | 2006-05-05 | 2012-11-30 | Транстек Фарма, Инк. | Белки слияния на основе rage, их композиции и способы их применения |
WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
MX2009013194A (es) | 2007-06-14 | 2010-03-30 | Galactica Pharmaceuticals Inc | Proteinas de fusion del receptor para productos finales de glicacion avanzada. |
WO2009063307A2 (en) * | 2007-11-14 | 2009-05-22 | Bio-Technology General (Israel) Ltd. | Inflammatory activity detection method using il-6 |
EP2421892A1 (en) | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
CN105148269A (zh) * | 2011-02-21 | 2015-12-16 | 菲布他丁有限合伙公司 | 治疗和诊断疾病的方法 |
CN105308460A (zh) * | 2013-05-02 | 2016-02-03 | 天主教大学基金会 | 个性化药物 |
CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US6340459B1 (en) * | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
IL155174A0 (en) * | 2000-10-02 | 2003-10-31 | Reddy Us Therapeutics Inc | Methods and compositions for the treatment of inflammatory diseases |
BR0116606A (pt) * | 2000-12-29 | 2006-05-09 | Reddy Us Therapeutics Inc | métodos e composições para detecção de compostos que modulam as respostas inflamatórias |
US7173032B2 (en) * | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
-
2001
- 2001-12-21 BR BRPI0116606-9A patent/BR0116606A/pt unknown
- 2001-12-21 EP EP01998128A patent/EP1368648A2/en not_active Withdrawn
- 2001-12-21 IL IL15665101A patent/IL156651A0/xx unknown
- 2001-12-21 PL PL01366250A patent/PL366250A1/xx unknown
- 2001-12-21 CA CA002433348A patent/CA2433348A1/en not_active Abandoned
- 2001-12-21 HU HU0600450A patent/HUP0600450A2/hu unknown
- 2001-12-21 US US10/026,335 patent/US7273712B2/en not_active Expired - Fee Related
- 2001-12-21 WO PCT/US2001/050818 patent/WO2002066978A2/en not_active Application Discontinuation
- 2001-12-21 JP JP2002566653A patent/JP2005501222A/ja active Pending
-
2003
- 2003-06-26 IS IS6861A patent/IS6861A/is unknown
- 2003-06-27 NO NO20032986A patent/NO20032986L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2433348A1 (en) | 2002-08-29 |
IS6861A (is) | 2003-06-26 |
US20020086282A1 (en) | 2002-07-04 |
PL366250A1 (en) | 2005-01-24 |
HUP0600450A2 (en) | 2006-09-28 |
EP1368648A2 (en) | 2003-12-10 |
US7273712B2 (en) | 2007-09-25 |
JP2005501222A (ja) | 2005-01-13 |
NO20032986L (no) | 2003-08-13 |
BR0116606A (pt) | 2006-05-09 |
WO2002066978A3 (en) | 2003-01-23 |
IL156651A0 (en) | 2004-01-04 |
WO2002066978A2 (en) | 2002-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20032986D0 (no) | Metoder og blandinger for påvisning av forbindelser som modulerer inflammatoriske responser | |
NO20023216D0 (no) | Instrumentert sementeringsplugg og system for samme | |
NO20030867D0 (no) | Hydroksamderivater anvendelig som deacetylaseinhibitorer | |
DK2253620T3 (da) | Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer | |
NO20032229L (no) | Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer | |
NO20033288L (no) | Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer | |
DE69719692D1 (de) | Video-Inspektions- oder Bohrlochmessgerät | |
DE69906311D1 (de) | Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren | |
DE60110061D1 (de) | Thermoelektrischer entfeuchter | |
NO20005400D0 (no) | Kinoloner anvendt som MRS-inhibitorer og baktericider | |
DE60108043D1 (de) | Zerstörungsfreies Inspektionsverfahren | |
PT1150991E (pt) | Composicoes para o tratamento da resposta inflamatoria | |
NO20040996L (no) | Nye forbindelser og sammensetninger som catepsin-inhibitorer | |
DK1337547T3 (da) | Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider | |
DE60214316D1 (de) | Chirp-Messverfahren | |
DK0962760T3 (da) | Indretning til evaluering af kvalitet af granulære objekter | |
DE69903319T2 (de) | Fkbp inhibitoren | |
PT1263421E (pt) | Avasimibe, o inibidor duplo da sintese de ester de colesterilo e de ester ceroso, para o tratamento de disturbios da glandula sebacea | |
DE60000251T2 (de) | Kompakte Gesichtsfeldtestanordnung | |
NO20014988D0 (no) | Pseudomycinantisoppsammensetninger og fremgangsmåter for anvendelser av disse | |
NO20026065D0 (no) | Prosesser for måling av dinofysistoksin og av yessotoksin | |
PT1267621E (pt) | Composicoes e metodos herbicidas sinergeticos | |
NO20015760L (no) | Fibrinforseglinger som tilveiebringer mindre betennelsesrespons og fremgangsmater for bruk av samme | |
NO20042492L (no) | Fremgangsmate for deteksjon og karakterisering av avleiringer i sanntid | |
NO20044424L (no) | Fremgangsmate for fremstilling av sertindol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |